In July, the European Medicines Agency began reviewing GLP-1 receptor agonists, including Ozempic, Saxenda and Wegovy, because of Icelandic patients reporting thoughts of suicide and self-harm. The U.S. has not launched a similar probe.
Read the full post on Becker's Hospital Review - Healthcare News
